4,888
Views
0
CrossRef citations to date
0
Altmetric
Editorial

ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?

ORCID Icon &
Pages 445-447 | Received 13 Dec 2021, Accepted 25 Jan 2022, Published online: 02 Feb 2022
 

Declaration of interests

H Hashmi is on advisory boards of Sanofi, Janssen and Bristol-Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

One of the peer reviewers on this manuscript is a named patent inventor on anti-CD38 antibodies. Two additional peer reviewers have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

The authors have no funding to report.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.